Home administration of lanreotide Autogel^® by patients with acromegaly, or their partners, is safe and effective

Authors: Bevan, J. S.¹; Newell-Price, J.²; Wass, J. A. H.³; Atkin, S. L.⁴; Bouloux, P. M.⁵; Chapman, J.⁶; Davis, J. R. E.⁷; Howlett, T. A.⁸; Randeva, H. S.⁹; Stewart, P. M.¹⁰; Viswanath, A.¹

Source: Clinical Endocrinology, Volume 68, Number 3, March 2008 , pp. 343-349(7)

Publisher: Blackwell Publishing

Key:

- Free Content

- New Content

- Subscribed Content

- Free Trial Content

Abstract:

Summary Objective

The introduction of ready-to-use lanreotide Autogel® has presented the possibility of patients receiving their acromegaly treatment at home. The objective of this study was to assess the ability of patients (or their partners) to administer repeat, unsupervised, injections of lanreotide Autogel without compromising efficacy or safety. Design

Multicentre (10 UK regional endocrine centres), open-label, nonrandomised, controlled study. Patients elected either to receive/administer unsupervised home injections after injection technique training (Test group) or continued to receive injections from a healthcare professional (Control group). Patients received monthly injections of lanreotide Autogel® at their established dose. Effects were monitored for up to 40 weeks. Patients

Thirty patients (15 per treatment group) with acromegaly treated with a stable dose of lanreotide Autogel® (60, 90 or 120 mg) for ≥ 4 months before screening. Measurements

The main outcome measure was the proportion of patients/partners who successfully administered injections throughout the study. Results

All Test group patients/partners qualified to administer injections. Fourteen of 15 patients fulfilled all criteria for successful administration of unsupervised injections (95% confidence interval, 70%-99%). Fourteen of 15 Test and 14/15 Control patients maintained growth hormone and IGF-1 control. Local injection tolerability was good for both treatment groups, and safety profiles were similar. All Test group patients continued with unsupervised injections after the study. Conclusions

Patients with acromegaly or their partners were able to administer lanreotide Autogel® injections with no detrimental effect on efficacy and safety; therefore, unsupervised home injections are a viable alternative to healthcare professional injections for suitably motivated patients.

Document Type: Research article

DOI: 10.1111/j.1365-2265.2007.03044.x

Affiliations: 1: Department of Endocrinology, Aberdeen Royal Infirmary, Foresterhill, Aberdeen, 2: Endocrine Unit, Royal Hallamshire Hospital, Sheffield, 3: Department of Endocrinology, Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Oxford, 4: Michael White Centre for Diabetes & Endocrinology, Hull Royal Infirmary, Hull, East Yorkshire, 5: Department of Endocrinology, The Royal Free Hospital, Hampstead, London, 6: Department of Endocrinology, Sunderland Royal Hospital, Sunderland, 7: Department of Endocrinology, Manchester Royal Infirmary, Manchester, 8: Department of Endocrinology, Leicester Royal Infirmary, Leicester, Leicestershire, 9: Department of Endocrinology, University Hospitals of Coventry & Warwickshire NHS Trust, Coventry and 10: Department of Medicine, Queen Elizabeth Hospital, Queen Elizabeth Medical Centre, Edgbaston, Birmingham, UK

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$50.16 plus tax Refund Policy